文献速递泌尿男性生殖肿瘤

TALAPRO-2 循环肿瘤 DNA 与细胞生物标志物分析

Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling.
PubMed 文献 · Lancet Oncol · 2026-10-28

TALAPRO-2 是一项随机双盲 3 期试验,探索 talazoparib 联合恩扎卢胺对比安慰剂联合恩扎卢胺在转移性 APMR 前列腺癌中的疗效。本探索性分析显示,前瞻性组织与回顾性 ctDNA 检测 HRR 状态一致性为 84%,基线 ctDNA 阳性、ctDNA 转阴及 CTC 转换均与影像学无进展生存相关。

要点

  • 组织与 ctDNA 检测 HRR 状态一致性 84%(421/501 可评估者)。
  • 第 9 周 ctDNA 转阴或 CTC 转换/CTC0 提示 rPFS 获益。

核心结论

  • ctDNA 负荷与 CTC 计数在转移性 APMR 前列腺癌中具有广泛预后价值,包括 PARP 抑制剂治疗背景下。

研究设计与样本

  • 本探索性分析评估前瞻性组织(FoundationOne CDx)与回顾性筛查 ctDNA(FoundationOne Liquid CDx)的 HRR 状态一致性,以及基线 ctDNA 负荷、ctDNA 转换、CTC 转换和 CTC0 的预后价值。

主要发现

  • HRR 状态一致性:92%(739/805)患者有 ctDNA 结果,其中可评估者 84%(421/501)一致。
  • 两组中第 9 周 ctDNA 由阳性转阴性均预示 rPFS 改善,持续 ctDNA 阴性者 rPFS 更优;第 9 周 CTC 转换和 CTC0 在两组均具预后价值。

临床怎么用

  • 可考虑用 ctDNA 检测补充组织 HRR 状态评估,尤其组织不可及时。
  • 基线 ctDNA 阳性提示预后较差,需加强监测与随访。
  • 治疗早期(如第 9 周)ctDNA 转阴或 CTC 转换/CTC0 可作为疗效获益的预后标志。

局限性

  • 本分析为探索性生物标志物分析,非预设主要终点。
  • HRR 一致性仅在可评估患者中报告,部分患者 ctDNA 检测不可评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The TALAPRO-2 trial showed improved radiographic progression-free survival and overall survival with first-line talazoparib plus enzalutamide versus placebo plus enzalutamide in patients with metastatic androgen pathway modulator-resistant prostate cancer (APMR; also referred to as castration-resistant prostate cancer) unselected for homologous recombination repair (HRR) gene alterations treated. We aimed to assess HRR gene alteration status agreement between prospective solid tumour tissue and circulating tumour DNA (ctDNA) testing, the potential complementary value of prospective and retrospective ctDNA testing, and the prognostic utility of baseline ctDNA burden, changes in ctDNA burden, and circulating tumour cell (CTC) reductions. METHODS: In TALAPRO-2, a randomised, double-blind, placebo-controlled, phase 3 trial, men aged 18 years or older (≥20 years in Japan) with asymptomatic or mildly symptomatic metastatic APMR prostate cancer and no previous life-prolonging systemic therapy for APMR disease were randomly assigned (1:1) to receive once daily, oral talazoparib 0·5 mg plus enzalutamide 160 mg or placebo plus enzalutamide and stratified by HRR gene alteration status and previous treatment for androgen pathway modulator-naive/sensitive disease. The sponsor, patients, and investigators were masked to allocation of talazoparib or placebo; enzalutamide was open label. In this exploratory analysis, HRR gene alteration status agreement was evaluated in the unselected intention-to-treat cohort between solid tumour tissue prospectively tested using a clinical trial assay based on FoundationOne CDx and retrospectively tested ctDNA samples, collected at screening and assessed using an assay based on FoundationOne Liquid CDx. Tumour burden was categorised as positive or negative (ctDNA tumour fraction detectable or not detectable). Reductions in CTCs, enumerated using CELLSEARCH, were defined as conversion (from five or more cells per 7·5 mL of blood to four or fewer cells per 7·5 mL of blood) or CTC0 (from one or more cells per 7·5 mL of blood to zero). Radiographic progression-free survival was assessed for patients with baseline ctDNA positivity (positive vs negative) and for patients with ctDNA conversion and CTC conversion and CTC0 at week 9 (and week 17 for CTC conversion and CTC0) by treatment group. This trial is registered with ClinicalTrial.gov, NCT03395197 and is active, not recruiting. FINDINGS: Between Jan 7, 2019, and Sept 17, 2020, 805 patients were enrolled and randomly assigned (402 to talazoparib plus enzalutamide; 403 to placebo plus enzalutamide); median follow-up for radiographic progression-free survival was 24·9 months (IQR 21·9-30·2) for the talazoparib group and 24·6 months (14·4-30·2) for the placebo group. A high concordance in HRR gene alteration status was observed between results from prospectively tested solid tumour tissue samples and retrospectively tested screening ctDNA samples (reported for 739 [92%] of 805 enrolled patients), with 84% (421 of 501) agreement in patients evaluable as either HRR-deficient or HRR-non-deficient by both tests. Median radiographic progression-free survival for positive versus negative ctDNA burden was 21·0 months (95% CI 16·5-not reached [NR]) versus NR (NR-NR), respectively (hazard ratio [HR] 2·46; 95% CI 1·68-3·60; p<0·0001) with talazoparib plus enzalutamide, and 11·0 months (8·4-13·8) versus 33·2 months (30·3-NR), respectively (HR 4·03; 2·85-5·72; p<0·0001) with placebo plus enzalutamide. In both groups, week 9 conversion from positive to negative ctDNA was prognostic of improved radiographic progression-free survival versus remaining ctDNA positive. Patients remaining ctDNA negative had more favourable radiographic progression-free survival versus conversion from positive to negative ctDNA. CTC conversion and CTC0 at week 9 were prognostic for radiographic progression-free survival benefit in both groups. INTERPRETATION: Our results support broad prognostic utility of ctDNA burden and CTC enumeration in metastatic APMR prostate cancer, including in the context of poly(ADP) ribose polymerase inhibitor therapy. FUNDING: Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Yip SM, Laird AD, Agarwal N, et al. Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling. Lancet Oncol. 2026. PMID: 42950862. doi:10.1016/S1470-2045(26)00355-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。